Malignant melanoma: genetics and therapeutics in the genomic era
L Chin, LA Garraway, DE Fisher - Genes & development, 2006 - genesdev.cshlp.org
Cell for cell, probably no human cancer is as aggressive as melanoma. It is among a handful
of cancers whose dimensions are reported in millimeters. Tumor thickness approaching 4 …
of cancers whose dimensions are reported in millimeters. Tumor thickness approaching 4 …
[HTML][HTML] CDK4: a master regulator of the cell cycle and its role in cancer
The cell cycle is regulated in part by cyclins and their associated serine/threonine cyclin-
dependent kinases, or CDKs. CDK4, in conjunction with the D-type cyclins, mediates …
dependent kinases, or CDKs. CDK4, in conjunction with the D-type cyclins, mediates …
Melanoma induction by ultraviolet A but not ultraviolet B radiation requires melanin pigment
Malignant melanoma of the skin (CMM) is associated with ultraviolet radiation exposure, but
the mechanisms and even the wavelengths responsible are unclear. Here we use a …
the mechanisms and even the wavelengths responsible are unclear. Here we use a …
The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma
The recent clinical success of targeted therapies in melanoma directed at the oncogene
BRAF validates the concept of targeting oncogenes. The p16-cyclin D-CDK4/6 …
BRAF validates the concept of targeting oncogenes. The p16-cyclin D-CDK4/6 …
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E–mutated melanomas
KSM Smalley, M Lioni, MD Palma, M **ao… - Molecular cancer …, 2008 - AACR
Recent studies have shown that there is a considerable heterogeneity in the response of
melanoma cell lines to MEK and BRAF inhibitors. In the current study, we address whether …
melanoma cell lines to MEK and BRAF inhibitors. In the current study, we address whether …
Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell …
RJ Young, K Waldeck, C Martin, JH Foo… - Pigment cell & …, 2014 - Wiley Online Library
We have investigated the potential for the p16‐cyclin D‐CDK 4/6‐retinoblastoma protein
pathway to be exploited as a therapeutic target in melanoma. In a cohort of 143 patients with …
pathway to be exploited as a therapeutic target in melanoma. In a cohort of 143 patients with …
CDK4: a key player in the cell cycle, development, and cancer
The cell cycle is regulated in part by cyclins and their associated serine/threonine cyclin-
dependent kinases, or CDKs. CDK4, in conjunction with the D-type cyclins, mediates …
dependent kinases, or CDKs. CDK4, in conjunction with the D-type cyclins, mediates …
The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation
V Yadav, TF Burke, L Huber, RD Van Horn… - Molecular cancer …, 2014 - AACR
B-RAF selective inhibitors, including vemurafenib, were recently developed as effective
therapies for melanoma patients with B-RAF V600E mutation. However, most patients …
therapies for melanoma patients with B-RAF V600E mutation. However, most patients …
Alpha-melanocyte–stimulating hormone suppresses oxidative stress through a p53-mediated signaling pathway in human melanocytes
AL Kadekaro, J Chen, J Yang, S Chen… - Molecular Cancer …, 2012 - AACR
Epidermal melanocytes are skin cells specialized in melanin production. Activation of the
melanocortin 1 receptor (MC1R) on melanocytes by α-melanocyte–stimulating hormone (α …
melanocortin 1 receptor (MC1R) on melanocytes by α-melanocyte–stimulating hormone (α …
Inhibition of tumor growth in vitro and in vivo by fucoxanthin against melanoma B16F10 cells
The present study was designed to evaluate the molecular mechanisms of fucoxanthin
against melanoma cell lines (B16F10 cells). Fucoxanthin reduced the proliferation of …
against melanoma cell lines (B16F10 cells). Fucoxanthin reduced the proliferation of …